Associate Researcher at Guilin Medical University, China
Yi Gou is a distinguished researcher in anticancer drug chemistry with a strong academic background and a track record of innovation. He has authored over 40 SCI papers, with a significant number of first-author publications. His groundbreaking research has led to multiple patents and contributions to international scientific literature. Yi has also served as a guest editor for renowned journals such as Frontiers in Pharmacology and Drug Development Research. His expertise and research are recognized globally, contributing to advancements in cancer therapy.
Publication Profile :
Scopus
Educational Background 🎓
Yi Gou earned a Ph.D. in Inorganic Chemistry in 2016. During his doctoral research, he specialized in the field of anticancer drug chemistry, laying the foundation for his subsequent work. His extensive education and training have provided him with a solid understanding of both inorganic chemistry and medicinal chemistry, particularly in designing and synthesizing anticancer small molecule agents. This expertise has guided his research in the development of novel drug candidates, and his academic achievements include numerous publications in high-impact journals.
Professional Experience 💼
Yi Gou is currently serving as an Associate Researcher at Guilin Medical University, where he continues his pioneering research on anticancer drug chemistry. His professional career includes both independent research projects and collaborative work, notably contributing to the National Natural Science Foundation of China (NSFC) projects. He has led one completed NSFC project (Project No. 22007023) and is actively conducting another (Project No. 22267004). In addition to his research, Yi Gou has also been recognized for his editorial contributions, serving as a guest editor for journals such as Frontiers in Pharmacology and Drug Development Research. Over the years, his work has resulted in numerous publications, patents, and positive evaluations in the international research community.
Research Interests 🔬
Yi’s primary research focus is on the design and synthesis of small molecule anticancer agents, particularly those involving metal-based complexes. His work merges the fields of inorganic chemistry and medicinal chemistry, with a focus on developing novel therapeutics to combat cancer. Yi has received significant funding for his research, completing one National Natural Science Foundation of China project (Project No. 22007023) and currently leading another (Project No. 22267004). His work has led to eight Chinese invention patents and multiple collaborations, including research on metal-antitumor complexes based on traditional Chinese medicine components.
Key Achievements
🔬 Over 40 published SCI papers, with an h-index of 24
📜 8 Chinese invention patents granted, 6 in the process of application
🔗 Collaborations with leading researchers and national projects
🌍 Recognized as a guest editor for prominent journals
🎓 Member of the Chinese Chemical Society
Publications 📚
- Li, A., Pan, W., Zhang, Z., Zhang, Y., & Ma, L. (2025). Hydrazone copper(II) complexes suppressed lung adenocarcinoma by activating multiple anticancer pathways. Bioorganic Chemistry, 154, 107994.
- Li, A., Huang, K., Pan, W., Ma, L., & Gou, Y. (2024). Thiosemicarbazone mixed-valence Cu(I/II) complex against lung adenocarcinoma cells through multiple pathways involving cuproptosis. Journal of Medicinal Chemistry, 67(11), 9091–9103.
-
Wu, Y., Wu, D., Lan, J., Xu, Y., & Gou, Y. (2024). Assessment of mononuclear/dinuclear copper acylhydrazone complexes for lung cancer treatment. Bioorganic Chemistry, 144, 107122.
-
Deng, J., Wu, Y., Li, A., Yang, F., & Gou, Y. (2023). Dithiocarbazate-Zn(II) complexes for photodynamic therapy and chemotherapy against lung cancer. Inorganic Chemistry Frontiers, 10(22), 6526–6536.
- Wu, Y., Hou, L., Lan, J., Liu, W., & Gou, Y. (2023). Mixed-ligand copper(II) hydrazone complexes: Synthesis, structure, and anti-lung cancer properties. Journal of Molecular Structure, 1279, 134986.
- Gou, Y., Liu, L., & Liang, H. (2022). Editorial: The developments of metal-based agents against lung cancer. Frontiers in Pharmacology, 13, 1101890.
- Chen, M., Chen, X., Huang, G., Gou, Y., & Deng, J. (2022). Synthesis, anti-tumour activity, and mechanism of benzoyl hydrazine Schiff base-copper complexes. Journal of Molecular Structure, 1268, 133730.
- Deng, J., Peng, C., Hou, L., Huang, G., & Gou, Y. (2022). Dithiocarbazate-copper complex loaded thermosensitive hydrogel for lung cancer therapy via tumor in situ sustained-release. Inorganic Chemistry Frontiers, 9(23), 6190–6201.
- Guo, J., Li, A., Guo, R., Jin, J., & Huang, G. (2022). C1orf74 positively regulates the EGFR/AKT/mTORC1 signaling in lung adenocarcinoma cells. PeerJ, 10, e13908.
- Gou, Y., Jia, X., Hou, L. X., Jiang, H. W., & Yang, F. (2022). Dithiocarbazate-Fe(III), -Co(III), -Ni(II), and -Zn(II) complexes: Design, synthesis, structure, and anticancer evaluation. Journal of Medicinal Chemistry, 65(9), 6677–6689.